Nvidia Expands Genomics Activities With Supercomputer, New Partnerships

Oct 07, 2020

|

Premium

CHICAGO – Nvidia is teaming with Oxford Nanopore Technologies, a branch of the UK's National Health Service, and two major pharmaceutical companies develop what the technology company said will be Britain's most powerful supercomputer.

Called Cambridge-1, the supercomputer will feature Nvidia DGX SuperPod supercomputing infrastructure, based on the company's recently introduced A100 graphics processing unit (GPU) and related DGX A100, a box that holds eight A100 processors and related server hardware to increase computational speed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

CMS Letter to Orig3n

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

And After the Test

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

Faster, But Not Fast Enough

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

PLOS Papers on Plasmodium vivax Variation in Ethiopia, Childhood BMI Loci, More

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.

Featured White Papers

Novel Artificial Intelligence (AI)-based Technology to Improve Oncology Clinical Trial Fulfillment

Compatibility of liquid biopsy assays on multiple sequencing platforms

From Synthetic Gene to Vaccine: Confidence with GeneArt Gene Synthesis Services A GenomeWeb eCase Study Transcript

Harnessing the Power of the Expi Protein Expression Systems in Vaccine Development A GenomeWeb eCase Study Transcript

Oct

21

Featured Webinar

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

Oct

26

Featured Webinar

Robust CNV Detection Using Whole-Exome Sequencing for Complex Cases

This webinar will discuss Genotypos Science Labs’ experience with a whole-exome sequencing solution supporting the detection of copy number variants (CNVs) for the management of complex cases.

Oct

27

Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Oct

28

Featured Webinar

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Menu

Nvidia Expands Genomics Activities With Supercomputer, New Partnerships

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

Not ready for premium?

Breaking News

PathogenDx Partners With Prevenio on Food Safety System

CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

Fluidigm Shares Rise on Selection of Saliva-Based COVID-19 Assay for Federal Surge Testing

FDA Reissues Emergency Use Authorization for Thermo Fisher Scientific COVID-19 Combo Kit

LumiraDx Gets FDA Emergency Use Authorization for PCR-Based Coronavirus Test

Coronavirus Testing Specimen Collection Devices From DNA Genotek, Clinical Enterprises Get FDA EUAs

The Scan

CMS Letter to Orig3n

And After the Test

Faster, But Not Fast Enough

PLOS Papers on Plasmodium vivax Variation in Ethiopia, Childhood BMI Loci, More

Featured White Papers

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Robust CNV Detection Using Whole-Exome Sequencing for Complex Cases

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

What's Popular?

Tempus Enters Infectious Disease Market With Large-Scale COVID-19 Testing, Data Initiative

Pacific Biosciences, Children's Mercy, Microsoft Collaborate on Rare Genetic Disease Diagnostics

NIH Kicks Off Second Stage of 4D Nucleome Program With $142M in Research Grants

Imec Adds Variant Calling to DNA Analytics Software to Accelerate Genome Analysis

MD Anderson's DrBioRight Automates Omics Analytics With Natural-Language Technology

Sponsorships

Menu

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

Not ready for premium?

What's Popular?

Sponsorships

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*